Innovations in Combination Therapy to Dominate COPD Treatment Market
The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.
To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.
With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.
To understand how our report can bring difference to your business strategy, Ask for a brochure
Dual and Triple Therapies Minimize Moderate and Severe Exacerbations
With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.
To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.
Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.
Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
Improved Bronchodilators Reduce Reversibility in Patients
Stakeholders in the chronic obstructive pulmonary disease treatment landscape are developing methods to reduce emphysema and the mortality rates of patients. This has instigated the need for combined bronchodilator response (BDR) in patients. Revenue of bronchodilators in the COPD treatment market is estimated to reach a value of ~US$ 5.5 billion by 2027; the second-highest amongst all drug classes. This is why, healthcare professionals are taking regular follow-ups on patients with combined-BDR. However, the results in combined-BDR are associated with greater frequency of exacerbations and symptoms of asthma. Thus, healthcare companies are increasing research to identify patients with asthma-COPD overlaps, and developing treatment alternatives that result in improved outcomes.
Studies published in the European Respiratory Journal stated that, bronchodilator reversibility might not distinguish asthma from COPD. It was also found that, the prevalence of bronchodilator reversibility was higher in patients with COPD than in asthma patients. Thus, with the help of bronchodilator response testing, healthcare companies are developing improved prebronchodilators that minimize the adverse effects in patients.
Stuck in a neck-to-neck competition with other brands? Request a custom report on “Chronic Obstructive Pulmonary Disease (COPD) Treatment Market”
Analysts’ Viewpoint on COPD Treatment Market
The chronic obstructive pulmonary disease treatment market is anticipated for high growth during the forecast period. Although retail pharmacies dominate more than half of the market share, online pharmacies are expected to experience steady growth in the market. Healthcare companies are introducing digital inhalers with built-in sensors for patients suffering from COPD. For instance, in December 2018, Teva Pharmaceutical Industries — a leading Israeli multinational pharmaceutical company, announced the launch of ProAir® Digihaler™ — a digital inhaler with Bluetooth wireless technology for patients with asthma and COPD. However, healthcare companies are developing improved therapies to reduce the reversibility of inhalers in patients. Thus, manufacturers should focus on increasing triple therapy treatment options to effectively minimize exacerbations.
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Scope of the Report
TMR’s report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global chronic obstructive pulmonary disease treatment market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic obstructive pulmonary disease treatment market during the forecast period.
The report is prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global COPD treatment market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approaches to study various phenomena in the global chronic obstructive pulmonary disease treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic obstructive pulmonary disease treatment market.
The report delves into the competition landscape of the global COPD treatment market. Key players operating in the global chronic obstructive pulmonary disease treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global COPD treatment market that have been profiled in this report.
Key Questions Answered in the COPD Treatment Market Report
- What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?
- What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?
- Will North America continue to remain the most profitable regional market for COPD treatment providers?
- Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?
- Which are the leading companies in the global COPD treatment market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global chronic obstructive pulmonary disease treatment market, and arrive at conclusions on the future growth prospects of the COPD treatment market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary sources referred to by analysts during the production of the global chronic obstructive pulmonary disease treatment market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the COPD treatment market as primary sources.
These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from chronic obstructive pulmonary disease treatment market leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global chronic obstructive pulmonary disease treatment market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on the future prospects of the global chronic obstructive pulmonary disease treatment market more reliably and accurately.